Trait
Impaired visuospatial constructive cognition
Reduced ability affecting mainly visuospatial cognition which may be tested using pattern construction (for example by Differential Ability Scales, which test a person's strengths and weaknesses across a range of intellectual abilities).
Summary
- Body system
- Abnormality of the nervous system
Reference genomeGRCh38hg38
Positions on gene and variant pages follow this choice, in this browser.
Read the genes linked to Impaired visuospatial constructive cognition, and the rest of your genome, with one test.
From $449Free shipping · Results in 6–8 weeks
Get my Genome Test35 genes linked to Impaired visuospatial constructive cognition
Changes in these genes cause rare conditions in which Impaired visuospatial constructive cognition is seen. Most people with this trait have none of those conditions, and a gene on this list says nothing about anyone's own genome.
| Gene | How often it is seen | Conditions |
|---|---|---|
| ADA2adenosine deaminase 2 | Often (30–79%) | In 1 condition |
| BPTFbromodomain PHD finger transcription factor | Often (30–79%) | In 1 condition |
| ELNelastin | Often (30–79%) | In 1 condition |
| KCNC3potassium voltage-gated channel subfamily C member 3 | Often (30–79%) | In 1 condition |
| MLXIPLMLX interacting protein like | Often (30–79%) | In 1 condition |
| MT-CO1mitochondrially encoded cytochrome c oxidase I | Often (30–79%) | In 1 condition |
| MT-CO2mitochondrially encoded cytochrome c oxidase II | Often (30–79%) | In 1 condition |
| MT-CO3mitochondrially encoded cytochrome c oxidase III | Often (30–79%) | In 1 condition |
| MT-ND1mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 | Often (30–79%) | In 1 condition |
| MT-ND4mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 | Often (30–79%) | In 1 condition |
| MT-ND5mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 | Often (30–79%) | In 1 condition |
| MT-ND6mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 | Often (30–79%) | In 1 condition |
| MT-TFmitochondrially encoded tRNA-Phe (UUU/C) | Often (30–79%) | In 1 condition |
| MT-THmitochondrially encoded tRNA-His (CAU/C) | Often (30–79%) | In 1 condition |
| MT-TL1mitochondrially encoded tRNA-Leu (UUA/G) 1 | Often (30–79%) | In 1 condition |
| MT-TQmitochondrially encoded tRNA-Gln (CAA/G) | Often (30–79%) | In 1 condition |
| MT-TS1mitochondrially encoded tRNA-Ser (UCN) 1 | Often (30–79%) | In 1 condition |
| MT-TS2mitochondrially encoded tRNA-Ser (AGU/C) 2 | Often (30–79%) | In 1 condition |
| MT-TWmitochondrially encoded tRNA-Trp (UGA/G) | Often (30–79%) | In 1 condition |
| PRKAR1Bprotein kinase cAMP-dependent type I regulatory subunit beta | Often (30–79%) | In 1 condition |
| PSMD12proteasome 26S subunit, non-ATPase 12 | Often (30–79%) | In 1 condition |
| ABCD1ATP binding cassette subfamily D member 1 | Sometimes (5–29%) | In 1 condition |
| CACNA1Hcalcium voltage-gated channel subunit alpha1 H | Sometimes (5–29%) | In 1 condition |
| DARS2aspartyl-tRNA synthetase 2, mitochondrial | Sometimes (5–29%) | In 1 condition |
| GABRA1gamma-aminobutyric acid type A receptor subunit alpha1 | Sometimes (5–29%) | In 1 condition |
| GABRB3gamma-aminobutyric acid type A receptor subunit beta3 | Sometimes (5–29%) | In 1 condition |
| GABRG2gamma-aminobutyric acid type A receptor subunit gamma2 | Sometimes (5–29%) | In 1 condition |
| HTThuntingtin | Sometimes (5–29%) | In 1 condition |
| JRKJrk helix-turn-helix protein | Sometimes (5–29%) | In 1 condition |
| MAPTmicrotubule associated protein tau | Sometimes (5–29%) | In 1 condition |
| NF1neurofibromin 1 | Sometimes (5–29%) | In 1 condition |
| NOTCH3notch receptor 3 | Sometimes (5–29%) | In 1 condition |
| PMPCApeptidase, mitochondrial processing subunit alpha | Sometimes (5–29%) | In 1 condition |
| POMT1protein O-mannosyltransferase 1 | Sometimes (5–29%) | In 1 condition |
| SLC2A3solute carrier family 2 member 3 | Sometimes (5–29%) | In 1 condition |
How often is among people with one of the gene's conditions, the most often across them, as the Human Phenotype Ontology records it. These pages describe traits and the research behind them; they are not a diagnosis, and a doctor or genetic counsellor is the person to ask about symptoms.
Broader traits
Where this comes from
- The Human Phenotype Ontology, release 2026-09-01: the trait, its names, its definition and the genes linked to it. Find out more at hpo.jax.org.
- Data release 2026.10.16-c6eea6bf.
One test. A lifetime of answers.
From $449Free shipping · Results in 6–8 weeks